Esmon C T
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
Thromb Haemost. 2001 Jul;86(1):51-6.
It is becoming increasingly clear that coagulation augments inflammation and that anticoagulants, particularly natural anticoagulants, can limit the coagulation induced increases in the inflammatory response. The latter control mechanisms appear to involve not only the inhibition of the coagulation proteases, but interactions with the cells that either generate anti-inflammatory substances, such as prostacyclin, or limit cell activation. Recent studies have demonstrated a variety of mechanisms by which coagulation, particularly the generation of thrombin, factor Xa and the tissue factor-factor VIIa complex, can augment acute inflammatory responses. Many of these responses are due to the activation of one or more of the protease activated receptors. Activation of these receptors on endothelium can lead to the expression of adhesion molecules and platelet activating factor, thereby facilitating leukocyte activation. Therefore, anticoagulants that inhibit any of these factors would be expected to dampen the inflammatory response. The three major natural anticoagulant mechanisms seem to exert a further inhibition of these processes by impacting cellular responses. Antithrombin has been shown in vitro to increase prostacyclin responses and activated protein C has been shown to inhibit a variety of cellular responses including endotoxin induced calcium fluxes in monocytes and the nuclear translocation of NFKB, a key step in the generation of the inflammatory response. In some, but not all, in vivo models, these natural anticoagulants have been able to inhibit endotoxin/E. coli-mediated leukocyte activation and to diminish cytokine elaboration (TNF, IL-6 and IL-8). Phase III clinical studies for treatment of patients with severe sepsis have been completed for APC, which was successful (1), and for antithrombin, which was not (2). A phase III trial with tissue factor pathway inhibitor is in progress. In this review, the mechanisms by which the different natural anticoagulants are thought to function will be reviewed.
越来越明显的是,凝血会加剧炎症,而抗凝剂,尤其是天然抗凝剂,可以限制凝血诱导的炎症反应增加。后者的控制机制似乎不仅涉及凝血蛋白酶的抑制,还涉及与产生抗炎物质(如前列环素)或限制细胞活化的细胞的相互作用。最近的研究已经证明了多种机制,通过这些机制,凝血,特别是凝血酶、因子Xa和组织因子-因子VIIa复合物的产生,可以增强急性炎症反应。许多这些反应是由于一种或多种蛋白酶激活受体的激活。这些受体在内皮细胞上的激活可导致黏附分子和血小板活化因子的表达,从而促进白细胞活化。因此,抑制这些因素中任何一种的抗凝剂都有望减轻炎症反应。三种主要的天然抗凝机制似乎通过影响细胞反应进一步抑制这些过程。体外研究表明,抗凝血酶可增加前列环素反应,活化蛋白C已被证明可抑制多种细胞反应,包括内毒素诱导的单核细胞钙通量和NFKB的核转位,这是炎症反应产生中的关键步骤。在一些(但不是所有)体内模型中,这些天然抗凝剂能够抑制内毒素/大肠杆菌介导的白细胞活化并减少细胞因子的产生(TNF、IL-6和IL-8)。治疗严重脓毒症患者的III期临床研究已完成,针对活化蛋白C的研究取得成功(1),而针对抗凝血酶的研究则未成功(2)。一项关于组织因子途径抑制剂的III期试验正在进行中。在这篇综述中,将回顾不同天然抗凝剂被认为发挥作用的机制。